Circulating pancreatic polypeptide concentrations predict visceral and liver fat content

Amir H Sam, Michelle L Sleeth, E Louise Thomas, Nurhafzan A Ismail, Norlida Mat Daud, Edward Chambers, Fariba Shojaee-Moradie, Margot Umpleby, Anthony P Goldstone, Carel W Le Roux, Paul Bech, Mark Busbridge, Rosemary Laurie, Daniel J Cuthbertson, Adam Buckley, Mohammad A Ghatei, Stephen R Bloom, Gary S Frost, Jimmy D Bell, Kevin G Murphy, Amir H Sam, Michelle L Sleeth, E Louise Thomas, Nurhafzan A Ismail, Norlida Mat Daud, Edward Chambers, Fariba Shojaee-Moradie, Margot Umpleby, Anthony P Goldstone, Carel W Le Roux, Paul Bech, Mark Busbridge, Rosemary Laurie, Daniel J Cuthbertson, Adam Buckley, Mohammad A Ghatei, Stephen R Bloom, Gary S Frost, Jimmy D Bell, Kevin G Murphy

Abstract

Context and objective: No current biomarker can reliably predict visceral and liver fat content, both of which are risk factors for cardiovascular disease. Vagal tone has been suggested to influence regional fat deposition. Pancreatic polypeptide (PP) is secreted from the endocrine pancreas under vagal control. We investigated the utility of PP in predicting visceral and liver fat.

Patients and methods: Fasting plasma PP concentrations were measured in 104 overweight and obese subjects (46 men and 58 women). In the same subjects, total and regional adipose tissue, including total visceral adipose tissue (VAT) and total subcutaneous adipose tissue (TSAT), were measured using whole-body magnetic resonance imaging. Intrahepatocellular lipid content (IHCL) was quantified by proton magnetic resonance spectroscopy.

Results: Fasting plasma PP concentrations positively and significantly correlated with both VAT (r = 0.57, P < .001) and IHCL (r = 0.51, P < .001), but not with TSAT (r = 0.02, P = .88). Fasting PP concentrations independently predicted VAT after controlling for age and sex. Fasting PP concentrations independently predicted IHCL after controlling for age, sex, body mass index (BMI), waist-to-hip ratio, homeostatic model assessment 2-insulin resistance, (HOMA2-IR) and serum concentrations of triglyceride (TG), total cholesterol (TC), and alanine aminotransferase (ALT). Fasting PP concentrations were associated with serum ALT, TG, TC, low- and high-density lipoprotein cholesterol, and blood pressure (P < .05). These associations were mediated by IHCL and/or VAT. Fasting PP and HOMA2-IR were independently significantly associated with hepatic steatosis (P < .01).

Conclusions: Pancreatic polypeptide is a novel predictor of visceral and liver fat content, and thus a potential biomarker for cardiovascular risk stratification and targeted treatment of patients with ectopic fat deposition.

References

    1. Britton KA, Fox CS. Ectopic fat depots and cardiovascular disease. Circulation. 2011;124:e837–e841.
    1. Kopelman PG. Obesity as a medical problem. Nature. 2000;404:635–643.
    1. Fox CS, Massaro JM, Hoffmann U, et al. Abdominal visceral and subcutaneous adipose tissue compartments: Association with metabolic risk factors in the Framingham Heart Study. Circulation. 2007;116:39–48.
    1. Thomas EL, Parkinson JR, Frost GS, et al. The missing risk: MRI and MRS phenotyping of abdominal adiposity and ectopic fat. Obesity (Silver Spring). 2012;20:76–87.
    1. Kojima S, Ueno N, Asakawa A, et al. A role for pancreatic polypeptide in feeding and body weight regulation. Peptides. 2007;28:459–463.
    1. Schwartz TW. Pancreatic polypeptide: A hormone under vagal control. Gastroenterology. 1983;85:1411–1425.
    1. Tong J, Utzschneider KM, Carr DB, et al. Plasma pancreatic polypeptide levels are associated with differences in body fat distribution in human subjects. Diabetologia. 2007;50:439–442.
    1. Sive AA, Vinik AI, van Tonder SV. Pancreatic polypeptide (PP) responses to oral and intravenous glucose in man. Am J Gastroenterol. 1979;71:183–185.
    1. Fabbrini E, Magkos F, Mohammed BS, et al. Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. Proc Natl Acad Sci U S A. 2009;106:15430–15435.
    1. Adrian TE, Bloom SR, Bryant MG, Polak JM, Heitz P. Proceedings: Radioimmunoassay of a new gut hormone-human pancreatic polypeptide. Gut. 1976;17:393–394.
    1. Levy JC, Matthews DR, Hermans MP. Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care. 1998;21:2191–2192.
    1. Thomas EL, Saeed N, Hajnal JV, et al. Magnetic resonance imaging of total body fat. J Appl Physiol (1985). 1998;85:1778–1785.
    1. Thomas EL, Hamilton G, Patel N, et al. Hepatic triglyceride content and its relation to body adiposity: A magnetic resonance imaging and proton magnetic resonance spectroscopy study. Gut. 2005;54:122–127.
    1. Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity. Hepatology. 2004;40:1387–1395.
    1. Smith JD, Borel AL, Nazare JA, et al. Visceral adipose tissue indicates the severity of cardiometabolic risk in patients with and without type 2 diabetes: Results from the INSPIRE ME IAA study. J Clin Endocrinol Metab. 2012;97:1517–1525.
    1. Stefan N, Kantartzis K, Machann J, et al. Identification and characterization of metabolically benign obesity in humans. Arch Intern Med. 2008;168:1609–1616.
    1. Sung KC, Kim SH. Interrelationship between fatty liver and insulin resistance in the development of type 2 diabetes. J Clin Endocrinol Metab. 2011;96:1093–1097.
    1. Hamaguchi M, Kojima T, Takeda N, et al. Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. World J Gastroenterol. 2007;13:1579–1584.
    1. Kotronen A, Peltonen M, Hakkarainen A, et al. Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors. Gastroenterology. 2009;137:865–872.
    1. Schwartz TW, Holst JJ, Fahrenkrug J, et al. Vagal, cholinergic regulation of pancreatic polypeptide secretion. J Clin Invest. 1978;61:781–789.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅